Researchers have determined that a copper compound known for decades may form the basis for a therapy for amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease.
In a new study just published in the Journal of Neuroscience, scientists from Australia, the United States (Oregon), and the United Kingdom showed in laboratory animal tests that oral intake of this compound significantly extended the lifespan and improved the locomotor function of transgenic mice that are genetically engineered to develop this debilitating and terminal disease.
In humans, no therapy for ALS has ever been discovered that could extend lifespan more than a few additional months. Researchers in the Linus Pauling Institute at Oregon State University say this approach has the potential to change that, and may have value against Parkinson’s disease as well.
“We believe that with further improvements, and following necessary human clinical trials for safety and efficacy, this could provide a valuable new therapy for ALS and perhaps Parkinson’s disease,” said Joseph Beckman, a distinguished professor of biochemistry and biophysics in the OSU College of Science.
“I’m very optimistic,” said Beckman, who received the 2012 Discovery Award from the OHSU Medical Research Foundation as the leading medical researcher in Oregon.
Read more . . .
The Latest on: Therapy for Lou Gehrig’s disease
[google_news title=”” keyword=”Therapy for Lou Gehrig’s disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Therapy for Lou Gehrig’s disease
- US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosison July 12, 2025 at 2:30 am
US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...
- Chip off the ALS block; No pattern? no problem; and Plasmin’s human loopholeon July 11, 2025 at 4:43 am
Stem cell tech simulates ALS, quantum tools decode quasicrystals, and cancer exploits a human mutation—three breakthroughs expose disease, disorder, and design.
- Klotho Neurosciences Shares Jump as FDA Grants Orphan Drug Status for ALS Therapyon July 10, 2025 at 5:52 am
Shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) surged 22% following news that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s gene therapy ...
- ALS Community Files Citizens’ Petition asking FDA to Approve NurOwn Stem Cell Therapyon July 7, 2025 at 7:03 am
New and Unprecedented Survival, Respiratory, and Biomarker Data Prove that NurOwn Helps People with ALS Live Longer and Live Stronger BREMERTON, WA / ACCESS Newswire / July 7, 2025 / On July 4, 1939, ...
- Amyotrophic Lateral Sclerosis Treatment Market 2025: Key Innovations and Forecast Growth Path to 2032on July 6, 2025 at 1:32 pm
Explore Our Free-Market Analysis Sample – Instant Access: – https://www.astuteanalytica.com/request-sample/amyotrophic-lateral-sclerosis-treatment-market ...
- New royalty-based investment model (IMAGE)on July 2, 2025 at 11:48 am
ALS — also often called Lou Gehrig’s disease — is a progressive, neurodegenerative disease with no cure. Despite its devastating impact, the pace of new therapy development has remained sluggish — ...
- Everything Eric Dane Has Shared About His ALS Diagnosis: 'I Don’t Think This Is The End of My Story'on June 13, 2025 at 10:44 am
Eric Dane announced his ALS diagnosis in April 2025. Here's everything Eric Dane has said about his ALS diagnosis and his health since he shared the news.
- What You Should Know About ALS, Also Known as Lou Gehrig’s Diseaseon May 2, 2025 at 4:59 pm
SATURDAY, May 3, 2025 (HealthDay News) — Amyotrophic lateral sclerosis (ALS) – known as Lou Gehrig’s Disease based on the iconic 1930s New York Yankee baseball player – is a ...
via Bing News
